Announcement no. 02, 2008
March 11, 2008: Annual report from 01.01.2007 to 31.12.2007
March 28, 2008: Shareholders meeting
May 28, 2008: Interim report - 3 months
August 28, 2008: Interim report - 6 months
November 26, 2008: Interim report - 9 months
Further information:
Christina Tønnesen, Investor Relations
Tel. no. (+45) 45 29 00 00, e-mail investor@bioporto.com
About BioPorto:
BioPorto develops and markets antibodies and antibody-based products, including
tests to diagnose human disease, both for the benefit of individual patients
and to promote efficiency in the health sector. The Company's developments
include a test (NGAL) to diagnose and monitor acute kidney damage.
BioPorto's strategy is to develop new methods based on its antibody portfolio
that can be patented and achieve a wide use in the diagnosis of various
diseases.
BioPorto was founded in 2000 and has about 25 employees. The Company's B shares
are listed on OMX Nordic Exchange Copenhagen (symbol: BIOP B). BioPorto is
owned by a group of shareholders, none of whom owns more than 5%.
www.bioporto.com
